Sinovac Biotech (SVA) Tops Q2 EPS by 5c

Sinovac Biotech (NASDAQ: SVA) reported Q2 EPS of $0.04, $0.05 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.7 million.

For earnings history and earnings-related data on Sinovac Biotech (SVA) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Pulmatrix (PULM) Reports Q2 Loss of $0.29
• Omega Flex (OFLX) Tops Q2 EPS by 27c